Back to EZorb Newsletter Index

EZorb

  

EZORB MONTHLY NEWSLETTER SEP 28, 2018

In this issue:

 

1. Share Success: Letters From Readers
2. Research News: Meta-Analysis Discovered Evidence Against PSA-Based Screening
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?
  

1. Share Success: Letters From Readers 


Letter I: From Christine

Received at Testimonial Submit Form Tuesday, April 10, 2018 at 18:50:21

(Unedited)

 

Hi, my name is Christine. I am 65 years old.

Over 2 years ago I started a walking program with gradual increases to 2 miles at a block of time. It started to get harder and harder with hip pains. I continued anyway because I needed the exercise.

I was diagnosed in February with Osteopenia. The doctor gave me a prescription with many side effects. I looked on the internet and found Ezorb.

I began taking March 10. In about a week I was about a third of the way into my walk when I realized my hips weren't hurting!

By the next week I hardly felt at all! This is great.

A month into it and I can do my 2 miles almost pain free! Awesome!

Still feel the hips bending down and getting up, but hoping overtime that will lessen too!

After all, results in a month are unbelievable.

Also taking Marvlix. Don't know if it is helping yet, but I had a patch of Psoriasis for over 3 years that NOTHING effected. It is getting smaller! Great products!


***************************************************

From the Desk of EZorb Newsletter Editor:

 
This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. We appreciate your effort.


2. Research News: Meta-Analysis Discovered Evidence Against PSA-Based Screening

 

Prostate-specific antigen (PSA)-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

"Clinicians and patients considering PSA based screening need to weigh these benefits against the potential short and long term harms of screening, including complications from biopsies and subsequent treatment, as well as the risk of overdiagnosis and overtreatment," they write.

Medicine Matters editorial board member Axel Merseburger (University Hospital Schleswig-Holstein, Lubeck, Germany) agreed with the authors' conclusions and noted that this meta-analysis could signal the end of the debate on PSA-based screening.

He anticipates that advances in magnetic resonance imaging (MRI)-based screening and the use of novel age-adjusted screening models, such as that being investigated in the PROBASE trial, "will change screening in the future."

The meta-analysis comprised data on 721,718 men enrolled in five randomized controlled trials - including the CAP trial published earlier this year - that compared PSA-based screening with usual care in men who did not have prostate cancer.

Across all trials, PSA-based screening did not appear to be associated with a significant reduction in all-cause or disease-specific mortality, with corresponding pooled incidence rate ratios (IRRs) of 0.99 and 0.96 relative to usual care. This equates to one less death from any cause and zero fewer prostate-cancer specific deaths for every 1000 individuals screened, say the study authors.

They note, however, that due to the considerable risk for bias in the majority of the included trials, the quality of evidence was low to moderate for the various analyses. But in a sensitivity analysis of the one trial considered to have the lowest risk for bias, the findings for all-cause mortality were similar to those of the main analysis, with an IRR of 1.00.

By contrast, the incidence of prostate cancer-specific mortality appeared to be lower with screening than with usual care, at an IRR of 0.79. In absolute terms, this translated into one less death for every 1000 men who underwent screening.

Additionally, in the main analysis, PSA-based screening was associated with an increased detection of early-stage prostate cancer (risk ratio=1.39) and a "modestly" reduced incidence of advanced prostate cancer (risk ratio=0.85), report Philipp Dahm – from the University of Minnesota in Minneapolis, USA - and team.

Although the data on screening-related harms were limited, they estimate that for every 1000 individuals screened, approximately 25 more men would report erectile dysfunction relative to no screening, while an additional three men would develop urinary incontinence and one more individual would be hospitalized for sepsis.

The authors of a related editorial say that more precise characterization of an individual's risk of developing nonaggressive or aggressive prostate cancer, "alongside less invasive methods of detecting potentially life-shortening disease are key to improving outcome for this most common of solid cancers."

Martin Rolan (University of Cambridge, UK) and colleagues conclude: "In the meantime, conversations with patients requesting a PSA test should explore their reasons for requesting a test and include evidence based discussions about possible harms and benefits of PSA testing - informed by the patient's ethnicity and family history - and about recent advances in the use of multi-parametric-MRI and active surveillance, which have the potential to reduce the harms of testing."

Original article appeared in 14-09-2018 | Prostate cancer | Highlight | Article.


3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

  

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ elixirindustry.com for a copy of the instructions.

 

 

5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

 

Back to EZorb Newsletter Index

 
  Copyright 2018 Elixir Industry